L-asparaginase (ASNase; EC 3.5.1.1), listed as a cytotoxic medicine for acute lymphoblastic leukemia (ALL) in the WHO Model List of Essential Medicines for children and adults [5,6], is used as a standard remission induction chemotherapy treatment option for newly diagnosed ALL cases and as a direct systemic chemotherapy prophylaxis of the central nervous system for standard-risk and high-risk ALL patients [7]. Here, ASPG is linked to acute lymphoblastic leukemia.